Amerikanische Gesellschaft für Hirudotherapie

South African Health Products Regulatory Authority

SAHPRA · South Africa · africa

Regulatory jurisdiction profileJurisdictional reference
Medical device clearednational regulator

South Africa's SAHPRA (created 2018, replacing the Medicines Control Council) — leech therapy regulated as a medical device under the Medicines and Related Substances Act; traditional-health practitioners under separate THP Council.

Regulatory Profile

Agency type
national regulator
Region
africa
Country
South Africa
Leech status
medical device cleared
Last ASH review
2026-05-25

Relevant Regulation Codes

  • Medicines and Related Substances Act, 1965 (Act 101 of 1965) as amended by Act 14 of 2015 (which created SAHPRA)
  • Traditional Health Practitioners Act, 2007 (Act 22 of 2007)
  • Medical Devices and IVDs Regulations, 2017

Prescriber Requirements

  • HPCSA (Health Professions Council of South Africa)-registered MD
  • SANC (South African Nursing Council)-registered nurse under physician's order
  • Traditional Health Practitioners Council registrants have separate scope, but leech therapy primarily delivered in biomedical clinical settings

Supply Chain & GMP

SAHPRA medical-device licensing per 2017 regulations; English-language IFU.

Import/Export Rules

SAHPRA import licence + Department of Agriculture, Land Reform and Rural Development clearance for live invertebrates. CITES via Department of Forestry, Fisheries and the Environment.

Reimbursement Context

National Health Insurance Act, 2023 implementation pending; private medical schemes (Discovery, Bonitas, GEMS) cover inpatient flap-salvage indications. Outpatient coverage rare.

ASH Editorial Notes

SAHPRA replaced the older MCC in February 2018. South Africa's parallel statutory framework for traditional health practitioners is unusual in Africa; leech therapy in clinical practice remains biomedical-led.

Related Jurisdictions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.